579
Views
18
CrossRef citations to date
0
Altmetric
Articles

Terpenoids from the roots of Alangium chinense

, , , , , , , , & show all
Pages 1025-1038 | Received 08 Jun 2015, Accepted 08 Aug 2015, Published online: 26 Oct 2015
 

Abstract

Two new norditerpenoids (1 and 2), four new sesquiterpenoids (3–6), and 22 known compounds (7–28) were isolated from an ethanolic extract of roots of Alangium chinense. The absolute configurations of 1–6 were assigned by experimental and calculated ECD spectra. The skeleton of the compounds (1 and 2) has been reported only one time so far. Compounds 1, 13, and 23 exhibited antiviral activity against coxsackie virus B3 with IC50 values of 38–67 μM. Compounds 8 and 9 displayed neuritis inhibitory activity against microglial inflammation factor, with IC50 values of 6.4 and 10.1 μM, respectively. None of the compounds were cytotoxic in the MTT assay.

Acknowledgments

The authors are grateful to the Department of Instrumental Analysis at our institute for UV, IR, NMR, and MS spectra measurements.

Disclosure statement

No potential conflict of interest was reported by the authors.

Additional information

Funding

This work was financially supported by grants from the National Natural Science Foundation of China [grant number 21132009], [grant number 21302226]; the National Science and Technology Project of China [grant number 2012ZX09301002-002].

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.